Phone-Based Quit-Smoking Support for People in a Lung Cancer Screening Program
Compares phone-based quit-smoking support with standard help in smokers having lung cancer screening.
Plain-language title generated from the registry record
Registry title: PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Key facts
- Where
- Pierre-Bénite, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 74 years old?
Source: NCT07921719, who can take part
Where in France
- Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique, Hôpital Lyon Sud, Hospices Civils de LyonPierre-Bénite, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT07921719
- Record updated
- 6 November 2026
- Original description
This prospective observational study aims to evaluate whether an intensive tele-tobacco cessation program delivered through the PROMETHEE platform improves smoking cessation among smokers participating in the French national lung cancer screening pilot program IMPULSION. Participants receiving the PROMETHEE pathway will be compared with matched controls receiving standard smoking cessation support available through IMPULSION. The primary endpoint is self-reported smoking cessation at 12 months.Read full original descriptionShow less
Evaluation of an Intensive Tele-Tobacco Cessation Program Compared With Standard Smoking Cessation Support in Participants of the French IMPULSION Lung Cancer Screening Program (PROMETHEE)
This prospective observational study aims to evaluate whether an intensive tele-tobacco cessation program delivered through the PROMETHEE platform improves smoking cessation among smokers participating in the French national lung cancer screening pilot program IMPULSION. Participants receiving the PROMETHEE pathway will be compared with matched controls receiving standard smoking cessation support available through IMPULSION. The primary endpoint is self-reported smoking cessation at 12 months.
Inclusion: PROMETHEE Group:; Enrolled in IMPULSION; Active smoker or smoking cessation within the previous month; Referred to PROMETHEE by an IMPULSION investigator; Control Group:; Enrolled in IMPULSION; Active smoker or smoking cessation within the previous month; Not referred to PROMETHEE; Selected from the IMPULSION database; Matched by age (±5 years) and sex.
Exclusion: Control subjects already included in PROMETHEE; Any exclusion criterion applicable under the IMPULSION program itself.